Dear reader,
We open this issue of Human Vaccines & Immunotherapeutics with a Profile of the biotech company TILT Biotherapeutics (Hemminki, p 970).
Next, the Hepatitis section presents analyses of antibody persistence 20 years after combined hepatitis A and B vaccination (Van Damme, p 972) as well as after priming in infancy versus adolescence (Romanò, p 981), a review of therapeutic hepatitis B vaccine development (Li, p 986), a survey of perceptions of hepatitis B vaccination among those being tested for sexually transmitted infections (Moyroud, p 998), a report on the awareness of the disease in Chinese rural areas (Zheng, p 1005), and a Commentary on the influence of obesity on vaccine immunogenicity (Liu, p 1014).
A review reports on progress in HIV vaccine development (Hsu, p 1018), and four articles give updates on the development of Novel Vaccines: a VLP-based vaccine against RSV (Hwang, p 1031), Hsp65-based tuberculosis vaccine (Wowk, p 1040), adjuvanted herpes zoster subunit vaccine (Godeaux, p 1051) and a review of dengue vaccine (Torresi, p 1059).
The Licensed Vaccines section introduces clinical and molecular characterization of severe pertussis in infants aged <6 months (Stefanelli, p1073), a report on a measles outbreak in a Spanish community (García Comas, p 1078), cost analysis of measles in refugees from Malaysia (Coleman, p 1084), and a Letter to the Editor on BCG, tuberculid and Kawasaki disease in Mexico and Japan (Gamez-Gonzalez, p 1091).
We are pleased to present four articles on Immunotherapy: a preclinical study of a CAR-hematopoietic stem cell-based cancer therapy (Larson, p 1094), and three Commentaries on targeting NO synthase (Ekmekcioglu, p 1105), predicting resistance to immunotherapy (Catani, p 1109) and antibody-inducing cancer vaccines (Huijbers, p 1112).
Three research articles on Rotavirus include economic evaluation of routine infant immunization in Japan (Hoshi, p 1115), analyses of immune responses to RV3-BB neonatal vaccine (Chen, p 1126) and vaccination-related iatrogenic pain (Yin, p 1136).
The Acceptance section consists of a prospective study of socio-demographic correlates of childhood vaccination status (Pati, p 1141), an introduction of a new vaccine-information mobile app ReadyVax (Bednarczyk, p 1149), and a commentary on digital tools for vaccine education (Wilson, p 1155).
We introduce a cost-effectiveness analysis of AS04-adjuvanted HPV 16/18 vaccine (Germar, p 1158) and a Letter to the Editor on the strategy for national HPV immunization program in Japan (Tanaka, p 1167).
Next, you will find a preclinical evaluation of a new 13-valent Pneumococcal vaccine (Park, p 1169) and a Commentary of herd effects of PCV in children (van Werkhoven, p 1177).
This issue of HV&I concludes with a report on Meningococcal carriage in Turkish adolescents (Tekin, p 1182), a Phase 3 clinical trial of the egg-based pre-pandemic Influenza A/H5N1 vaccine MG1109 (Song, p 1190), and a review on the Public Health aspects of vaccination of healthcare workers (Ozisik, p 1198).
Our monthly News, Policy and Profiles (NP&P) track offers a selection of the latest news in the field of vaccines and immunotherapeutics. In this section we also regularly publish opinion pieces on timely, interesting and controversial topics related to vaccines and immunotherapeutics, profiles of companies and organizations, as well as portraits of distinguished scientists in our field. Please contact Acquisitions Editor Adam Weiss ( [email protected]) with your ideas for commentaries, opinion pieces, profiles and portraits. Your suggestions for and contributions to our N&P&P track are always welcome!
Sincerely,
Ronald Ellis, PhD
Editor-in-Chief
Adam Weiss, PhD
Acquisitions Editor